

<p style="text-align: center;">LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)</p>	ATTY DOCKET NO. 11068-065-999	APPLICATION NO 10/612,603
	APPLICANT <i>Chappay et al.</i>	
	FILING DATE July 1, 2003	GROUP 1646

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
HH	A01	5,436,131	7/25/95	Condra <i>et al.</i>			
	A02	5,837,464	11/17/98	Capon <i>et al.</i>			
	A03	6,033,902	3/7/00	Haseltine <i>et al.</i>			
	A04	6,103,462	8/15/00	Paulous <i>et al.</i>			
↓	A05	6,242,187	6/5/01	Capon <i>et al.</i>			

FOREIGN PATENT DOCUMENTS


		DOCUMENT NUMBER	DATE	COUNTRY	CLAS S	SUBCLA SS	TRANSLAT ION	YES	NO
HH	A06	WO99/67427	6/99	PCT					
HH	A07	Int'l Search Report for PCT/US03/21335	5/3/04	PCT					

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

HH	A08	Condra <i>et al.</i> , (1996), "Genetic Correlates of In Vivo Resistance to Indinavir, a Human Immunodeficiency Virus Type 1 Protease Inhibitor," <i>Journal of Virology</i> , 70(12): 8270-76
	A09	Genbank Accession Number AF324493 HIV-1 vector pNL4....[gi:12831134] (2001).
	A10	Gervais <i>et al.</i> , (1997), "A New Reporter Cell Line to Monitor HIV Infection and Drug Susceptibility <i>in Vitro</i> ," <i>Proc. Natl. Acad. Sci. USA</i> , 94:4653-4658.
	A11	Gong <i>et al.</i> , (2000), "In Vitro Resistance Profile of the Human Immunodeficiency Virus Type 1 Protease Inhibitor BMS-232632," <i>Antimicrobial Agents and Chemotherapy</i> , 44(9): 2319-26.
	A12	Gunthard <i>et al.</i> , (1998), "Comparative Performance of High-Density Oligonucleotide Sequencing and Dideoxynucleotide Sequencing of HIV Type 1 <i>pol</i> From Clinical Samples", <i>Aids Research and Human Retroviruses</i> , 14(10): 869-876..
	A13	Haubrich <i>et al.</i> , (2001), "CCTG 575: A Randomized. Prospective Study of Phenotype Testing Versus Standard of Care For Patients Failing Antiretroviral Therapy," <i>Antiviral Therapy</i> , 6(Supplement 1): 63.
	A14	Herrmann <i>et al.</i> , (1997), "A Working Hypotheses-Virus Resistance Development As An Indicator of Specific Antiviral Activity," <i>Ann. NY Acad Sciences</i> , 284: 632-637.
	A15	Hertogs <i>et al.</i> , (1998), "A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates From Patients Treated with Antiretroviral Drugs," <i>Antimicrobial Agents and Chemotherapy</i> , 42(2): 269-276.
	A16	Hirsch <i>et al.</i> , (2000), "Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection," <i>JAMA</i> , 283(18): 2417-26.
	A17	Katzenstein <i>et al.</i> , (2002), "Baseline Phenotypic Susceptibility and Virologic failure over 144 weeks Among Nucleoside RT Inhibitor Experienced Subjects in ACTG 364," <i>Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection</i> , "2002 9 th Conference on Retroviruses and Opportunistic Infections, Session 77 Poster Session 591-T.
	A18	Katzenstein <i>et al.</i> , (2002), "The Inhibitory Quotient (IQ) for Saquinavir (SQV) Predicts Virologic Response to Salvage Therapy," <i>2002 9th Conference on Retroviruses and Opportunistic Infections</i> , Session 28 Poster Session 129.
	A19	Maguire <i>et al.</i> , (2002), "Emergence of Resistance to Protease Inhibitor Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients: Selection of Four Alternative Viral Protease Genotypes and Influence of Viral Susceptibility to Coadministered Reverse Transcriptase Nucleoside Inhibitors," <i>Antimicrobial Agents and Chemotherapy</i> , 46(3): 731-738.
↓	A20	Petropoulos <i>et al.</i> , (2000), "A Novel Phenotypic Drug Susceptibility Assay For Human Immunodeficiency Virus Type 1," <i>Antimicrobial Agents and Chemotherapy</i> , 44(4): 920-928.

LF	A21	Race <i>et al.</i> , (1999), "Analysis of HIV Cross-Resistance to Protease Inhibitors Using A Rapid Single-Cycle Recombinant Virus Assay For Patients Failing On Combination Therapies," <i>AIDS</i> , 13(15): 2061-2068.
↓	A22	Schuurman <i>et al.</i> , (1999), "Worldwide Evaluation of DNA Sequencing Approaches for Identification of Drug Resistance Mutations in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase," <i>Journal of Clinical Microbiology</i> , 37(7): 2291-2296.
↓	A23	Shi <i>et al.</i> , (1997), "A Recombinant Retroviral System for Rapid In Vivo Analysis of Human Immunodeficiency Virus Type 1 Susceptibility to reverse Transcriptase Inhibitors," <i>Antimicrobial Agents and Chemotherapy</i> , 41(12): 2781-85.
EXAMINER		
	DATE CONSIDERED 2/1/2006	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY DOCKET NO. 11068-065-999 APPLICATION NO 10/612,603

APPLICANT
Chappey *et al.*

FILING DATE July 1, 2003 GROUP 1645

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
HH	B01	5,766,842	6/98	Melnick <i>et al.</i>			
	B02	20020064838	5/02	Parkin <i>et al.</i>			
↓	B03	20030108857	6/03	Parkin <i>et al.</i>			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	YES	NO
HH	B04	WO00/78996	12/00	PCT					
	B05	WO02/22076	3/02	PCT					
	B06	WO02/068618	9/02	PCT					
	B07	WO02/099387	12/02	PCT					
	B08	WO03/070700	8/03	PCT					
	B09	WO04/003512	1/04	PCT					
	B10	WO04/003514	1/04	PCT					
	B11	Int'l Search Report for PCT/US00/17178	12/00	PCT					
	B12	Int'l Search Report for PCT/US01/28754	3/02	PCT					
	B13	Int'l Search Report for PCT/US02/01682	9/02	PCT					
	B14	Int'l Search Report for PCT/US02/18684	1/03	PCT					
	B15	Int'l Search Report for PCT/US03/04362	12/04	PCT					
↓	B16	Int'l Search Report for PCT/US03/21023	7/04	PCT					

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

HH	B17	Carrillo <i>et al.</i> , (1998), "In Vitro Selection and Characterization of Human Immunodeficiency Virus Type 1 Variants With Increased Resistance to ABT-378, a Novel Protease Inhibitor," <i>Journal of Virology</i> , 72(9): 7532-41.
	B18	Craig <i>et al.</i> , 1998 "HIV Protease Genotype and Viral Sensitivity to HIV Protease Inhibitors Following Saquinavir Therapy", <i>AIDS</i> , 12: 1611-1618.
	B19	Dreyer GB, <i>et al.</i> "A Symmetric Inhibitor Binds HIV-1 Protease Asymmetrically" <i>Biochemistry</i> (1993) 32:937-947
	B20	J. Eron, <i>et al.</i> , (1995) Preliminary Assessment of 141 W94 in Combination with Other Protease Inhibitors," <i>5th Conference on Retroviruses and Opportunistic Infections</i> :
	B21	Genbank Accession Number P12497 POL Polyprotein (2004)
↓	B22	Hazuda, <i>et al.</i> , 2000 "Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in Cells," <i>Science</i> 287: 646-650.

JUL 13 2004




B23	Hill, A. et al. (1998) "Low frequency of genotypic mutations associated with resistance to AZT and 3TC after combination treatment with indinavir," <i>Int. Conf. AIDS</i> 12:812, (Abstract No. 6)
B24	Kempf et al., (2001), "Identification of Genotypic Changes in Human Immunodeficiency Virus Protease that Correlate With Reduced Susceptibility to the Protease Inhibitor Lopinavir Among Viral Isolates From Protease Inhibitor-Experienced Patients," <i>Journal of Virology</i> , 75(16): 7462-69.
B25	Kim, (1995) " Crystal Structure of HIV-1 Protease in Complex with VX-478, a Potent and Orally Bioavailable Inhibitor of the Enzyme," <i>J. Am. Chem. Soc.</i> , 117: 1181-1182
B26	Lambert DM, et al. (1992) "Human Immunodeficiency Virus Type 1 Protease Inhibitors Irreversibly Block Infectivity of Purified Virions From Chronically Infected Cells" <i>Ant Microb Agents Chem</i> 36:982-98
B27	Larder, et al., (1995) "Potential Mechanism for; Sustained Antiretroviral Efficacy of AZT-3TC Combination Therapy," <i>Science</i> , 269; 696-699
B28	Lazdins, et al., (1997) "In Vitro Effect of al-Acid Glycoprotein on the Anti-Human Immunodeficiency Virus (HIV) Activity of the Inhibitor CGP 61775: A Comparative Study wits Other Relevant HIV Protease Inhibitors," <i>J Infec. Dis.</i> , 175: 1063-1070
B29	Livingston, et al., (1995) "Weak Binding of VX-478 to Human Plasma Proteins and Implications for Anti-Human Immunodeficiency Virus Therapy," <i>J Infec. Dis.</i> , 172:1.238-124
B30	Mahalingam, et al., (1999) "Structural and Kinetic Analysis of Drug Resistant Mutants of HIV Protease," <i>Biochem.</i> , 263: 1-9
B31	Miller M, et al. (1989) "Structure of Complex of Synthetic HIV-lj Protease with a SubstrateBased Inhibitor at 2.3 A Resolution, <i>Science</i> 246:1149-1152
B32	Mohri H, et al. (1993) "Quantitation of Zidovudine-Resistant Human Immunodeficiency Virus Type 1 in the Blood of Treated and Untreated Patients," <i>PNAS</i> 90:25-29
B33	Murphy, et al., (1999) "Treatment with Amprenavir Alone or Amprenavir with Zidovudine and Lamivudine in Adults with Human Immunodeficiency Virus Infection" <i>J. Infec. Dis.</i> , 179: 808-81 E
B34	Najera I, et al. (1994) "Natural Occurrence of Drug ResistancE Mutations in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 Isolates," <i>Aids Res Hum Retroviruses</i> 10:1479-1488
B35	Najera I, et al. (1995) "pol Gene Quasispecies of Human Immunodeficiency Virus: Mutations Associated with Drug ResistancE in Virus From Patients Undergoing No Drug Therapy," <i>J Virol</i> 69:23-31
B36	Palmer, et al., (1999) "Highly Drug-resistant HIV-1 Clinical Isolates Are Cross-resistant to Many Antiretroviral Compounds in Current Clinical Development," <i>AIDS</i> , 13: 661-667
B37	Parkin, et al., (1999) "Phenotypic changes in Drug Susceptibility Associated with Failure of Human Immunodeficiency Virus Type 1 (HIV-1) Triple Combination Therapy," <i>J Infec. Dis.</i> , 180: 865-870
B38	Partaledis, et al., (1995) "In Vitro Selection and Characterization of Human Immunodeficiency Virus Type 1 (HIV-1) Isolates with Reduced Sensitivity to Hydroxyethylamino Sulfonamide Inhibitors of HIV-1 Aspartyl Protease," <i>Journal of Virology</i> , 69: 5228-5235
B39	Patnick, et al., (1998) "Genotypic and Pheno typic Ch aracterization of Human Immunodeficiency Virus Type 1 Variants Isolated from Patients Treated with the Protease Inhibitor Nelfinavir," <i>Antimicrobial Agents and Chemotherapy</i> , 42(10): 2637-44.
B40	Petit SC, et al. (1993) "The Specificity of the HIV-1 Protease" <i>Drug Discov Des</i> 1:69-83
B41	Roberts NA, et al. (1990) "Rational Design of Peptide-Based HIV Proteinase" <i>Science</i> 248:358361
B42	Roberts, N. A., (1995) "Drug-resistance patterns of saquinavir and other HIV proteinase inhibitors," <i>AIDS</i> .9 (supp 2) S27-S32
B43	Rusconi, Stefano. et al. (2000): "Susceptibility to PNU-140690 (Tipranavir) of Human Immunodeficiency Virus Type 1 Isolates Derived From Patients with Multidrug Resistance to Other Protease Inhibitors," <i>Antimicrobial Agents and Chemotherapy</i> , 44(5): 1328-32.
B44	Sadler, et al., (1999) "Safety and Pharmacokinetics of Amprenavir (141W94), a Human Immunodeficiency Virus (HIV) Type 1 Protease Inhibitor, Following Oral Administration of Single Doses to HIV-Infected Adults," <i>Antimicrobial Agents and Chemotherapy</i> , 43: 1686-1692
B45	Sarkar, et al., (1990) "The "Megaprimer" Method of Site-Directed Mutagenesis," <i>BioTech</i> 8(4):404-407
B46	Smidt, et al., (1996) "A Mutation in Human Immunodeficiency Virus Type 1 Protease at Position 88, Located Outside the Active Site, Confers Resistance to the Hydroxyethylurea Inhibitor SC-55389A," <i>Antimicrobial Agents and Chemotherapy</i> , 41: 515-522
B47	St. Clair, et al., (1996) "In Vitro Antiviral Activity of 141 W94 (VX-478) in Combination with Other Antiretroviral Agents," <i>Antiviral Research</i> 29: 53-56
B48	Tian, et al., (1998) "Zidovudine/Lamivudine Co-resistance Is Preceded by a Transient Period of Zidovudine Hypersensitivity," 2nd International Workshop on HIV Drug Resistance and Treatment Strategies, Abstract 30
B49	Tisdale, M. et al. (1998): "Genotypic and phenotypic analysis of HIV from patients on ZDV/3TC/amprenavir combination therapy," <i>Int. Conf AIDS</i> 12:583 (Abstract No. 32312)
B50	Tisdale, M. et al. (1995): "Cross-Resistance Analysis of Human Immunodeficiency Virus Type 1 Variants Individually Selected for Resistance to Five Different Protease Inhibitors," <i>Antimicro. Agents and Chemo.</i> 39(8):1704-10.
B51	Tucker, et al., (1998) "Estimate of the Frequency of Human Immunodeficiency Virus Type 1 Protease Inhibitor Resistance Within Unselected Virus Populations In Vitro," <i>Antimicrobial Agents and Chemotherapy</i> , 42: 478-480

61 P E
JUL 13 2004 9:15 AM
TRADEMARK COPIES
H H

Sheet 3 of 3

B52	Young <i>et al.</i> J. Infect. Disease 178(5) 1497-1501 (1998)
B53	Ziermann, <i>et al.</i> , (2000), "A Mutation in Human Immunodeficiency Virus Type 1 Protease, N88S, That Causes In Vitro Hypersensitivity to Amprenavir," <i>Journal of Virology</i> , 74(9): 4414-4419.
EXAMINER	<i>Lennert</i>
	DATE CONSIDERED 2/1/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY DOCKET NO.	APPLICATION NO
	11068-065-999	10/612,603
	APPLICANT	
	Chappay et al.	
FILING DATE	GROUP	
July 1, 2003	1645	

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>CH</i>	C01	Andrew Chin, March 9, 2002, "On the Preparation and Utilization of Isolated and Purified Oligonucleotides" (Paper Copy and CD-ROM included)
-----------	-----	---

EXAMINER	<i>CH</i>	DATE CONSIDERED	<i>2/1/2006</i>
----------	-----------	-----------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.